Effect of intralesional verapamil for treatment of Peyronie's disease: A randomized single-blind, placebo-controlled study

International Urology and Nephrology

Volumn 41, Issue 3, 2009, Pages 467-471

  Shirazi, M ^a   Haghpanah, A R ^a   Badiee, M ^a   Afrasiabi, M A ^a   Haghpanah, S ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Intralesional injection; Peyronie's disease; Verapamil

Indexed keywords

PLACEBO; SODIUM CHLORIDE; VERAPAMIL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; ERECTILE DYSFUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PENIS CURVATURE; PENIS DISEASE; PEYRONIE DISEASE; PLAQUE SIZE; PLAQUE SOFTENING; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

CALCIUM CHANNEL BLOCKERS; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; PENILE INDURATION; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; VERAPAMIL;

EID: 67649970858     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-009-9522-4     Document Type: Article

References (30)

1. Smith CJ, Mcmahon C, Shabsigh R (2005) Peyronie's disease: The epidemiology, aetiology and clinical evaluation of deformity. BJU Int 95:729-732. doi: 10.1111/j.1464-410X.2005.05391.x
2. Gelbard MK, Dorey F, James K (1990) The natural history of Peyronie's disease. J Urol 144:1376-1379
3. De la Peyronie F (1743) Sur quelques obstacle qui s opposent a l ejaculation naturelle de la semence. Mem Acad Chir (Paris) 1:318
4. Sommer F, Schwarzer U, Wassmer G et al (2002) Epidemiology of Peyronie's disease. Int J Impot Res 14:379-383. doi: 10.1038/sj.ijir.3900863
5. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U (2001) The prevalence of Peyronie's disease: Results of a large survey. BJU Int 88:727-730. doi: 10.1046/j.1464-4096.2001.02436.x
6. Fitkin J, Ho GT (1999) Peyronie's disease: Current management. Am Fam Physician 60:549-552
7. Tunuguntlas HS (2001) Management of Peyronie's disease: A review. World J Urol 19:244-250. doi: 10.1007/s003450100209
8. Anderson MS, Shankey TV, Lubrano T, Mulhall JP (2000) Inhibition of Peyronie's plaque fibroblast proliferation by biologic agents. Int J Impot Res 12(suppl 3):s25-s31. doi: 10.1038/sj.ijir.3900558
9. Lee RC, Ping J (1990) Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J Surg Res 49:463-466. doi: 10.1016/0022-4804(90)90197-A
10. Doong H, Dissanayaka S, Gowrishankar TR, La Barbera MC, Lee RC (1996) The 1996 Lindberg Award. Calcium antagonists alter cell shape and induce procollagenase synthesis in keloid and normal human dermal fibroblasts. J Burn Care Rehabil 17:497-514. doi: 10.1097/00004630-199611000-00005
11. Roth M, Eickelberg O, Kohler E, Eme P, Block LH (1996) Ca channel blockers modulate metabolism of collagenase within the extracellular matrix. Proc Natl Acad Sci USA 93:5478-5482. doi: 10.1073/pnas.93.11.5478
12. Levine LA (1997) Treatment of Peyronie's disease with intralesional verapamil injection. J Urol 158(4):1395-1399. doi: 10.1016/ S0022-5347(01)64224-1
13. Rehman J, Benet A, Melman A (1998) Use of intralesional verapamil to dissolve Peyronie's disease plaque: A long-term single blind study. Urology 51(4):620-626. doi: 10.1016/S0090-4295(97)00700-0
14. Levine LA, Merrick PF, Lee RC (1994) Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 151(6):1522-1524
15. Devine CJ Jr, Somers KD, Jordan GH et al (1997) Proposal trauma as the cause of the Peyronie's lesion. J Urol 157:285-290. doi: 10.1016/ S0022-5347(01)65361-8
16. Greenfield JM, Levine LA (2005) Peyronie's disease: Etiology, epidemiology and medical treatment. Urol Clin North Am 32:469-478. doi: 10.1016/j.ucl.2005.08.011
17. Scott WW, Scardino PL (1948) A new concept in the treatment of Peyronie's disease. South Med J 41:173-177
18. Akkus E, Carrier S, Rehman J et al (1994) Is colchicine effective in Peyronie's disease? A pilot study. Urology 44(2):291-295. doi: 10.1016/ S0090-4295(94)80155-X
19. Zarafonetis CJ, Horrax TM (1959) Treatment of Peyronie's disease with potassium para-aminobenzoate (potaba). J Urol 81(6):770-772
20. Ralph DJ, Brooks MD, Bottazzo GF et al (1992) The treatment of Peyronie's disease with tamoxifen. Br J Urol 70(6):648-651
21. Biagiotti G, Cavallini G (2001) Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: A preliminary report. BJU Int 88(1):63-67. doi: 10.1046/j.1464-410x.2001.02241.x
22. Ralph DJ, AL-Akraa M, Pryor JP (1995) The Nesbit operation for Peyronie's disease: 16-year experience. J Urol 154:1362-1363. doi: 10.1016/S0022-5347(01)66862-9
23. Devine CJ, Horton CE (1974) Surgical treatment of Peyronie's disease with a dermal graft. J Urol 111:44
24. Lue TF, El-Sakka AI (1998) Venous patch graft for Peyronie's disease. Part I. technique. J Urol 160:2047-2049. doi: 10.1016/ S0022-5347(01)62239-0
25. Wilson SK, Cleves MA, Delk JR (2001) Longterm follow-up of treatment for Peyronie's disease: Modelling the penis over an inflatable penile prosthesis. J Urol 165:825-829. doi: 10.1016/S0022-5347(05)66537-8
26. Carson CC (1998) Penile prosthesis implantation in the treatment of Peyronie's disease. Int J Impot Res 10:125-128. doi: 10.1038/ sj.ijir.3900330
27. Levine LA, Sevier VL (2003) A double blind, placebo-controlled trial of electromotive drug administration (EMDA) using verapamil vs. saline for Peyronie's disease: Preliminary results. J Urol 169(4):274-275
28. Levine LA, Goldman KE, Greenfield JM (2002) Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol 168(2):621-625. doi: 10.1016/S0022-5347(05)64691-5
29. Sahin M, Basar MM, Bozdogan O, Atan A (2001) Short-term histopatholoic effects of different intracavernosal agents on corpus cavernosum and antifibrotic activity of intracavernosal verapamil: An experimental study. Urology 58:487-492. doi: 10.1016/S0090-4295(01)01211-0
30. Bennett NE, Guhring P, Mulhall JP (2007) Intralesional verapamil prevents the progression of Peyronie's disease. Urology 69:1181-1184. doi: 10.1016/j.urology.2006.02.048